黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses.

Eur J Pharm Sci. 2019; 
ZhangJiantao,HuYanmei,HauRaymond,MusharrafiehRami,MaChunlong,ZhouXu,ChenYin,Wan
Products/Services Used Details Operation
Catalog Antibody After centrifugation, the supernatant was mixed with Protein A Sepharose beads (GE Healthcare) plus anti-Flag (GenScript, A00187) or anti-HA (Invitrogen, 71-5500) antibody and incubated overnight at 4 °C. Get A Quote

摘要

Influenza virus infection causes substantial morbidity and mortality worldwide. The limited efficacy of oseltamivir in delayed treatment, coupled with the increasing incidences of oseltamivir-resistant strains, calls for next-generation of antiviral drugs. In this study, we discovered NMS-873, an allosteric and specific p97 inhibitor, as a broad-spectrum influenza antiviral through forward chemical genomics screening. NMS-873 shows potent antiviral activity with low-nanomolar ECs against multiple human influenza A and B viruses, including adamantine-, oseltamivir-, or double resistant strains. Our data further showed that silencing of p97 via siRNA or inhibiting p97 by NMS-873 both inhibited vir... More

关键词

Broad-spectrum antiviral,Host-targeting antiviral,Influenza virus,NMS-873